Diagnostic Testing and Identifying L-2-HGA

At a Glance

L-2-HGA is identified by combining chiral urine testing to separate L-2HG from D-2HG, supportive brain MRI findings, and testing for two appropriately interpreted disease-causing L2HGDH variants on opposite gene copies; MLPA or deletion testing may find changes missed by standard sequencing.

Because L-2-hydroxyglutaric aciduria (L-2-HGA) is so rare and its symptoms develop slowly, reaching a definitive diagnosis typically involves a combination of three complementary pillars of evidence: biochemical testing, brain imaging, and genetic confirmation. However, a molecular diagnosis may be established without all three pillars, and MRI is supportive rather than pathognomonic ^[1]^[2]. These tests allow doctors to distinguish L-2-HGA from other similar-looking conditions and provide a clear explanation for the symptoms ^[1]^[2].

The Broken Pathway: Why L-2HG Builds Up

In every person, the body naturally produces a substance called L-2-hydroxyglutarate (L-2HG) as a byproduct of normal energy production ^[3]. To keep this substance from reaching toxic levels, the body uses a specialized enzyme called L2HGDH ^[4].

Think of this enzyme as a metabolic “recycler.” Its job is to take L-2HG and turn it back into a useful molecule called 2-oxoglutarate ^[5]. When the L2HGDH gene has mutations (variants), this recycler stops working. As a result, L-2HG cannot be cleared and begins to accumulate in the blood, urine, and brain, leading to the symptoms of the disease ^[4]^[6].

Pillar 1: Chiral Differentiation (The Urine Test)

The first step in diagnosis is often a urine organic acid test. However, a standard test is usually not enough. There are two “mirror image” versions of this molecule: L-2HG and D-2HG ^[7].

Why it matters: While they look almost identical, they are caused by completely different genetic problems. D-2-hydroxyglutaric aciduria (D-2-HGA) is a separate condition with its own set of challenges ^[8]^[9].
The requirement: To confirm L-2-HGA, the lab must use chiral differentiation. This is a specialized laboratory technique (often using LC-MS/MS) that can physically separate the L- form from the D- form ^[10]^[7]. If a test only reports “total 2-hydroxyglutarate,” it cannot tell the difference between the two conditions.

Pillar 2: The Characteristic MRI Pattern

L-2-HGA creates a very specific “signature” on a brain MRI that helps specialists recognize it.

Centripetal White Matter Changes: The most striking feature is a symmetric change in the white matter (the brain’s wiring). This typically shows a distribution pattern extending inward (centripetal) from the subcortical U-fibers ^[1]^[11].
Deep Brain Involvement: Doctors also look for changes in the dentate nuclei (a part of the cerebellum involved in coordination) and the basal ganglia (structures that help control movement) ^[11]^[12].
Distinguishing from GA-I: This pattern is different from other conditions like Glutaric Aciduria Type I (GA-I), which typically shows wide spaces around the temples and different patterns of brain injury ^[13].

Pillar 3: Genetic Sequencing and Deletion Testing

The final step for diagnosis is identifying changes in the L2HGDH gene—one inherited from each parent ^[14]^[15].

To confirm the diagnosis, two pathogenic (disease-causing) variants must be appropriately interpreted and shown to be on opposite gene copies; a variant of uncertain significance does not confirm L-2-HGA. Sometimes, standard gene sequencing (which “reads” the DNA like a book) only finds one mutation or none at all, even if the urine and MRI results strongly suggest L-2-HGA. In these cases, doctors must perform MLPA (Multiplex Ligation-dependent Probe Amplification) or deletion/duplication testing ^[16]^[17].

Why it’s needed: Standard sequencing can miss large “chunks” of DNA that are missing (deletions) or extra (duplications). MLPA is one possible next step that checks if any of these large pieces are missing ^[17], though it does not detect every missed variant and may be supplemented by broader copy-number analysis and parental testing. Finding these hidden mutations is often the final piece of the puzzle for families who have waited years for an answer.

Common questions in this guide

What tests are used to diagnose L-2-HGA?

Doctors usually combine a urine organic acid test that separates the L and D forms of 2-hydroxyglutarate, a brain MRI, and genetic testing of L2HGDH. A molecular diagnosis may establish L-2-HGA even if all three types of evidence are not present.

Why does an L-2-HGA urine test need to distinguish L- and D-2-hydroxyglutarate?

L-2-hydroxyglutarate and D-2-hydroxyglutarate are mirror-image forms caused by different genetic conditions. A result showing only total 2-hydroxyglutarate cannot tell L-2-HGA from D-2-HGA, so the laboratory needs chiral differentiation, often using a specialized method such as LC-MS/MS.

What MRI findings can support an L-2-HGA diagnosis?

Brain MRI may show symmetric changes in the white matter that extend inward from the brain’s outer wiring, along with changes in the dentate nuclei and basal ganglia. These findings support L-2-HGA but are not by themselves definitive, so doctors interpret them with urine and genetic results.

What does it mean if genetic sequencing finds only one L2HGDH variant?

One identified variant does not always exclude L-2-HGA when urine and MRI findings are suggestive. Doctors may order MLPA, deletion or duplication testing, broader copy-number testing, and sometimes parental testing to look for a second change that standard sequencing missed.

Can a variant of uncertain significance confirm L-2-HGA?

No. A variant of uncertain significance is not considered proof of disease; molecular confirmation generally requires two appropriately interpreted, disease-causing L2HGDH variants on opposite copies of the gene, usually one inherited from each parent.

How are L-2-HGA and similar conditions such as D-2-HGA or GA-I distinguished?

Chiral urine testing helps distinguish the L form from the D form of 2-hydroxyglutarate, while MRI patterns may help separate L-2-HGA from Glutaric Aciduria Type I. Genetic testing provides additional confirmation and helps doctors interpret the results together.

Get notified when new evidence is published on L-2-hydroxyglutaric aciduria.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Key takeaways

L-2-HGA diagnosis typically draws on chiral urine organic acid testing, brain MRI, and L2HGDH genetic analysis, although a molecular diagnosis may be established without all three.
Chiral differentiation separates L-2-hydroxyglutarate from D-2-hydroxyglutarate because total 2-hydroxyglutarate cannot distinguish L-2-HGA from D-2-HGA.
MRI may show symmetric inward-spreading white-matter changes involving the dentate nuclei and basal ganglia, but MRI is supportive rather than definitive.
If sequencing finds one or no L2HGDH variant, MLPA, deletion or duplication testing, broader copy-number analysis, and parental testing may identify changes that sequencing missed.
Molecular confirmation requires two appropriately interpreted pathogenic L2HGDH variants on opposite copies of the gene; a variant of uncertain significance does not confirm L-2-HGA.

References (17)

1
L-2-hydroxyglutaric aciduria - review of literature and case series.
Ahmed S, Siddiqui A, DeBerardinis RJ, et al.
Annals of medicine and surgery (2012) 2023; (85(4)):712-717 doi:10.1097/MS9.0000000000000326.
PMID: 37113859
2
Cerebral neoplasm in L-2-hydroxyglutaric aciduria: two different presentations.
Dilber B, Havalı C, Eroglu N, et al.
Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2020; (36(7)):1545-1548 doi:10.1007/s00381-019-04466-9.
PMID: 31858216
3
Mitochondrial L-2-hydroxyglutarate is a physiological signalling metabolite.
Chakrabarty RP, Van Vranken JG, Aoi Y, et al.
Nature 2026; (655(8124)):1037-1047 doi:10.1038/s41586-026-10564-x.
PMID: 42162436
4
Structure and biochemical characterization of l-2-hydroxyglutarate dehydrogenase and its role in the pathogenesis of l-2-hydroxyglutaric aciduria.
Yang J, Chen X, Jin S, Ding J
The Journal of biological chemistry 2024; (300(1)):105491 doi:10.1016/j.jbc.2023.105491.
PMID: 37995940
5
Plants Possess a Cyclic Mitochondrial Metabolic Pathway similar to the Mammalian Metabolic Repair Mechanism Involving Malate Dehydrogenase and l-2-Hydroxyglutarate Dehydrogenase.
Hüdig M, Maier A, Scherrers I, et al.
Plant & cell physiology 2015; (56(9)):1820-30 doi:10.1093/pcp/pcv108.
PMID: 26203119
6
A Pathogenic L2HGDH Variant Impairs Mitochondrial Targeting and Enzyme Function in L-2-Hydroxyglutaric Aciduria: Clinical and Functional Evidence from Two Affected Siblings.
Guo Q, Löhr T, Giavalisco P, et al.
Genes 2025; (16(8)) doi:10.3390/genes16080982.
PMID: 40870031
7
Quantitative Analysis of Oncometabolite 2-Hydroxyglutarate.
Yuan BF
Advances in experimental medicine and biology 2021; (1280()):161-172 doi:10.1007/978-3-030-51652-9_11.
PMID: 33791981
8
Separation and quantification of the urinary enantiomers of 2-hydroxyglutaric acid by capillary electrophoresis with capacitively coupled contactless conductivity detection: Application to the diagnosis of D- and L-2-hydroxyglutaric aciduria.
Cansever MŞ, Öztekin N, Kıykım E, et al.
Journal of separation science 2023; (46(16)):e2300145 doi:10.1002/jssc.202300145.
PMID: 37269210
9
D-2-hydroxyglutaric aciduria in a patient with speech delay due to a novel homozygous deletion in the D2HGDH gene.
Phillips E, Sasarman F, Sinasac DS, Al-Hertani W
Molecular genetics and metabolism reports 2019; (20()):100482 doi:10.1016/j.ymgmr.2019.100482.
PMID: 31431883
10
In-vivo brain H1-MR-Spectroscopy identification and quantification of 2-hydroxyglutarate in L-2-Hydroxyglutaric aciduria.
Anghileri E, Bertolino N, Salsano E, et al.
Brain research 2016; (1648(Pt A)):506-511 doi:10.1016/j.brainres.2016.08.013.
PMID: 27543339
11
The broad spectrum of clinical manifestations observed in three patients with L2 hydroxyglutaric aciduria spans from febrile seizures to complex dystonia.
Alsayed A, Albadrani M, Obaid A, et al.
Molecular genetics and metabolism reports 2024; (41()):101135 doi:10.1016/j.ymgmr.2024.101135.
PMID: 39262645
12
Genetic, neuroimaging, and clinical characteristics of a cohort of individuals with L-2-hydroxyglutaric aciduria from Türkiye.
Engin Erdal A, Özbey SZ, Civelek Ürey GB, et al.
Journal of pediatric endocrinology & metabolism : JPEM 2025; (38(9)):956-963 doi:10.1515/jpem-2025-0021.
PMID: 40660807
13
Glutaric aciduria and L-2-hydroxyglutaric aciduria: Clinical and molecular findings of 35 patients from Turkey.
Bozaci AE, Er E, Ünal AT, et al.
Molecular genetics and metabolism reports 2023; (36()):100979 doi:10.1016/j.ymgmr.2023.100979.
PMID: 37275239
14
Riboflavin treatment in L-2-hydroxyglutaric aciduria: report on a pediatric patient and literature review.
Lipiński P, Ciara E, Bogdańska A, et al.
Journal of applied genetics 2026; (67(2)):443-449 doi:10.1007/s13353-025-00974-4.
PMID: 40380983
15
A novel compound heterozygous mutation of the L2HGDH gene in a Chinese boy with L-2-hydroxyglutaric aciduria: case report and literature review.
Zhang Y, Wang C, Yang K, et al.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2018; (39(10)):1697-1703 doi:10.1007/s10072-018-3483-2.
PMID: 29980873
16
Loss of function variants in L2HGDH gene causing L-2-hydroxyglutaric aciduria.
Bellad A, Holla VV, Kumari R, et al.
Acta neurologica Belgica 2023; (123(6)):2315-2323 doi:10.1007/s13760-023-02318-7.
PMID: 37378753
17
A novel protein truncating mutation in L2HGDH causes L-2-hydroxyglutaric aciduria in a consanguineous Pakistani family.
Muzammal M, Ali MZ, Brugger B, et al.
Metabolic brain disease 2022; (37(1)):243-252 doi:10.1007/s11011-021-00832-2.
PMID: 34719772

This page is for informational purposes only and does not constitute medical advice. A qualified healthcare professional should interpret your L-2-HGA urine, MRI, and genetic test results.